We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
4.19 | 3.27% | 132.50 | 130.13 | 127.50 | 127.80 | 5,217,690 | 01:00:00 |
Form 20-F [X]
|
Form 40-F [ ]
|
Yes [ ]
|
No [X]
|
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
3,580,000
|
|
1,356,236,954
|
1 June 2015
|
170,000
|
386.54
|
65,711,715
|
2 June 2015
|
200,000
|
386.11
|
77,221,620
|
3 June 2015
|
200,000
|
383.53
|
76,706,900
|
4 June 2015
|
175,000
|
379.16
|
66,353,053
|
Accumulated under the programme
|
4,325,000
|
|
1,642,230,241
|
Media: | ||
Anne Margrethe Hauge
|
+45 3079 3450
|
amhg@novonordisk.com
|
|
|
|
Investors: | ||
Kasper Roseeuw Poulsen
|
+45 3079 4303
|
krop@novonordisk.com
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Frank Daniel Mersebach (US)
|
+1 609 235 8567
|
fdni@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
24 25 67 90
|
Company announcement No 35 / 2015
|
Date: June 8, 2015
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions